Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer

Linderholm, Barbro; Hellborg, Henrik; Johansson, Ulla; Elmberger, Göran; Skoog, Lambert; Lehtiö, Janne; Lewensohn, Rolf

doi:10.1093/annonc/mdp062

Cited by 294 publications

(173 citation statements)

References 31 publications

Supporting

Mentioning

156

Contrasting

Unclassified

Order By: Relevance

“…Triplenegative are more aggressive breast cancers that lack hormone receptor expression and HER2 overexpression. 23 In agreement with Linderholm's study, 24 our data showed higher levels of VEGF in this group. Moreover, TNBCs, such as BRCA1/2 mutation carriers, also showed higher levels of Ang-1 and Ang-2 mRNA.…”

Section: Discussionsupporting

confidence: 92%

Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer

et al. 2012

View full text Add to dashboard Cite

Angiogenesis leads to the formation of blood vessels from pre-existing ones, allowing tumor growth. Vascular endothelial growth factor (VEGF) and Angiopoietins (Ang-1, Ang-2) have a pivotal role in tumor angiogenesis but few data regarding their role in hereditary breast cancer are available. The aim of the present study was to analyze Ang-1, Ang-2, tyrosine-protein kinase receptor Tie2 and VEGF expression and their correlation in a cohort of familial and sporadic breast cancers in order to verify whether the presence of germline mutations in BRCA may have a role in tumor microenvironment regulation. Tumor samples from a cohort of 41 patients with a first diagnosis and a family history of breast cancer and 19 patients with sporadic breast cancers were enrolled. The expression of Tie2, Ang-1, Ang-2 and VEGF were analyzed by quantitative real-time PCR. Patients harboring BRCA mutations had higher levels of Ang-1 (P ¼ 0.05), Ang-2 (P ¼ 0.02) and VEGF (P ¼ 0.04) mRNA compared with those without BRCA mutations (BRCAX). The same was observed in triple-negative breast cancer (TNBC). Moreover, a positive correlation between Ang-2 and VEGF was found in both the familial breast cancer group (BRCA carriers: r ¼ 0.83; Po0.0001 and BRCAX: r ¼ 0.58; P ¼ 0.008) and in TNBC (r ¼ 0.62; P ¼ 0.007). The higher levels of Ang-1, Ang-2 and VEGF mRNA found in BRCA carriers and TNBCs suggest that they could be attractive angiogenic therapeutic targets in these breast cancers.

show abstract

Section: Discussionsupporting

confidence: 92%

Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Patients with remaining preserved tumor homogenates were included in the present study. Patients were identified by use of the Breast Cancer registry data base at the Regional Oncologic Centre, Karolinska University Hospital, Stockholm, Sweden, and are in detail described in previous publications [15][16]. Patients with locally advanced breast cancer, presence of distant metastasis at diagnosis, or those subjected to neoadjuvant therapy were not included.…”

Section: Patientsmentioning

confidence: 99%

Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer

Linderholm¹,

Hellborg²,

Johansson³

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Внутриопухолевая экспрессия VEGF на-много выше при TНРМЖ, чем при не ТНРМЖ [13], что обеспечивает биологическую обосно-ванность применения ингибиторов ангиоге-неза для лечения больных ТНРМЖ.…”

Section: Wwwmalignanttumorsorg журнал «злокачественные опухоли»unclassified

Triple negative breast cancer: current status of the problem and unusual case of treatment

Муфазалов¹,

Шарипова²

2015

Zlokač. opuholi

View full text Add to dashboard Cite

Тройной негативный рак молочной железы: современное состояние проблемы и не совсем обычный случай лечения МУФАЗАЛОВ Ф.Ф., ШАРИПОВА Н.С.В статье представлен обзор литературных данных о клинических исследованиях, посвященных лечению тройного негативного рака молочной железы (ТНРМЖ), рассматривается активность существующих таргетных и химиопре-паратов. Описан не совсем обычный случай клинического течения и лечения ТНРМЖ.The article presents a review of clinical trials of treatment the triple negative breast cancer (TNBC). It considered the activity of existing target agents and chemotherapy. Described is not an ordinary case of the clinical course and treatment of TNBC.Ключевые слова: тройной негативный рак молочной железы, клинический случай. Контактная информация:Муфазалов Фагим Фанисович -заместитель главного врача по радиологии, доктор медицинских наук, профессор, главный радиолог МЗ Республики Башкортостан, вице-президент Российской Ассоциации терапевтических радиационных онкологов (РАТРО). ГБУЗ «Республиканский клинический онкологический диспансер» МЗ республики Башкортостан, г. Уфа. Шарипова Наиля Саматовна -врач-радиолог ГБУЗ «Республиканский клинический онкологический диспансер» МЗ республики Башкортостан, г. Уфа,

show abstract

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer

Abstract: Our results show that TNBC have higher i.t. VEGF levels compared with non-TNBC. Ongoing clinical trials will answer if therapy directed towards angiogenesis may be an alternative way to improve outcome in this poor prognosis group.

Cited by 294 publications

References 31 publications

Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer

Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer

Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer

Triple negative breast cancer: current status of the problem and unusual case of treatment

Contact Info

Product

Resources

About